LEIDEN, The Netherlands, April 11, 2018 /PRNewswire/ —
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM), the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, announces publication of its 2017 annual report and issues an invitation to its Annual General Meeting for all shareholders.
eTN Chatroom for Readers (join us)
Pharming’s annual report, including its management report and 2017 financial statements, is available for download on the company website [ https://www.pharming.com/investor-media/shareholders/public-reports/ ]. Printed copies will be available at the Annual General Meeting.
Annual General Meeting of Shareholders
Pharming’s upcoming Annual General Meeting will be held at the Holiday Inn (Haagse Schouwweg 10, Leiden, The Netherlands) on the 23rd of May 2018 at 14:00 CET.
The Notice to Convene, the Explanatory Notes and a Form of Proxy can be found on our website at http://www.pharming.com under Investors & Media/Shareholders/Shareholders’ Meetings.
About Pharming Group N.V.
Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
RUCONEST® is distributed by Pharming in Austria, France, Germany, Luxembourg, the Netherlands, the United Kingdom and the United States of America. Pharming holds commercialisation rights in Algeria, Andorra, Bahrain, Belgium, Ireland, Jordan, Kuwait, Lebanon, Morocco, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, United Arab Emirates and Yemen. In some of these countries RUCONEST® is made available on a named-patient basis in association with the HAEi Global Access Program (GAP).
RUCONEST® is distributed by Swedish Orphan Biovitrum AB (publ) (SS: SOBI) in the other EU countries, and in Azerbaijan, Belarus, Georgia, Iceland, Kazakhstan, Liechtenstein, Norway, Russia, Serbia and Ukraine.
Google News, Bing News, Yahoo News, 200+ publications
RUCONEST® is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama, and Venezuela by Cytobioteck, in South Korea by HyupJin Corporation and in Israel by Megapharm.
RUCONEST® has recently completed a clinical trial for the treatment of HAE in young children (2-13 years of age) and is also being evaluated for various additional follow-on indications.
Pharming’s technology platform includes a unique, GMP-compliant validated process for the production of pure recombinant human proteins that has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way compared with current cell-line based methods. Leads for enzyme replacement therapy (“ERT”) for Pompe and Fabry’s diseases are being optimized at present, with additional programs not involving ERT also being explored at an early stage.
Pharming has a long-term partnership with the China State Institute of Pharmaceutical Industry (“CSIPI”), a Sinopharm company, for joint global development of new products, starting with recombinant human Factor VIII for the treatment of Haemophilia A. Pre-clinical development and manufacturing will take place to global standards at CSIPI and will be funded by CSIPI. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.
Pharming has declared that the Netherlands is its “Home Member State” pursuant to the amended article 5:25a paragraph 2 of the Dutch Financial Supervision Act.
Additional information is available on the Pharming website: http://www.pharming.com
This press release of Pharming Group N.V. and its subsidiaries (“Pharming“, the “Company“ or the “Group“) may contain forward-looking statements including without limitation those regarding Pharming‘s financial projections, market expectations, developments, partnerships, plans, strategies and capital expenditures.
The Company cautions that such forward-looking statements may involve certain risks and uncertainties, and actual results may differ. Risks and uncertainties include without limitation the effect of competitive, political and economic factors, legal claims, the Company‘s ability to protect intellectual property, fluctuations in exchange and interest rates, changes in taxation laws or rates, changes in legislation or accountancy practices and the Company‘s ability to identify, develop and successfully commercialize new products, markets or technologies.
As a result, the Company‘s actual performance, position and financial results and statements may differ materially from the plans, goals and expectations set forth in such forward-looking statements. The Company assumes no obligation to update any forward-looking statements or information, which should be taken as of their respective dates of issue, unless required by laws or regulations.
Pharming Group N.V.
Sijmen de Vries, CEO
Robin Wright, CFO
Julia Phillips/Victoria Foster Mitchell
Lifespring Life Sciences Communication
BRON Pharming Group N.V.
To post and circulate your own press release on FIR and the eTN Network please click here